Psychosocial functioning Measured by: clinicians and self‐rated Timing of outcome assessment: end of treatment · patients with borderline personality disorder
1 finding from 1 review
Interpersonal problems Timing of outcome assessment: end of treatment (32 days to 24 weeks) · patients with borderline personality disorder
1 finding from 1 review
Self‐harm Measured by: clinicians Timing of outcome assessment: end of treatment · patients with borderline personality disorder
It is very uncertain whether antipsychotics changes self‐harm Timing of outcome assessment: end of treatment (8 to 24… compared with placebo (very low certainty).
1 finding from 1 review
Attrition Timing of outcome assessment: end of treatment · patients with borderline personality disorder
Mood stabilisers may leads to lower attrition Timing of outcome assessment: end of treatment (32 days to… compared with placebo (low certainty).
1 finding from 1 review
Non‐serious adverse events Timing of outcome assessment: end of treatment · patients with borderline personality disorder
It is very uncertain whether mood stabilisers changes non‐serious adverse events Timing of outcome assessment: end of… compared with placebo (very low certainty).
1 finding from 1 review
Suicide‐related outcomes Timing of outcome assessment: end of treatment (6 to 12 weeks treatment duration) · patients with borderline personality disorder
1 finding from 1 review
Psychosocial functioning Measured by: clinicians and self‐rated Timing of outcome assessment: end of treatment · patients with borderline personality disorder
1 finding from 1 review
Interpersonal problems Timing of outcome assessment: end of treatment (32 days to 24 weeks) · patients with borderline personality disorder
1 finding from 1 review
Attrition Timing of outcome assessment: end of treatment · patients with borderline personality disorder
It is very uncertain whether antipsychotics changes attrition Timing of outcome assessment: end of treatment (5 weeks to… compared with placebo (very low certainty).
1 finding from 1 review
Non‐serious adverse events Timing of outcome assessment: end of treatment · patients with borderline personality disorder
It is very uncertain whether antipsychotics changes non‐serious adverse events Timing of outcome assessment: end of… compared with placebo (very low certainty).
1 finding from 1 review
BPD symptom severity Measured by: clinicians and self‐rated Timing of outcome assessment: end of treatment · patients with borderline personality disorder
1 finding from 1 review
Health‐related quality of life (HRQoL) · women with early breast cancer
1 finding from 1 review
no estimate extracted
1 study · 1 participants
Low
Initiation of white spot lesions (WSL), visual-tactile assessment · Patients of any age (11-40 years) receiving comprehensive/fixed orthodontic treatment with fixed appliances
For a glass-ionomer-based bonding agent (single study), fluoride release significantly reduced WSL initiation (RR 0.64); subgroup not separately GRADE-rated.
1 finding from 1 review
Initiation of white spot lesions (WSL), visual-tactile assessment · Patients of any age (11-40 years) receiving comprehensive/fixed orthodontic treatment with fixed appliances
Among fluoride-releasing sealants, the reduction in WSL initiation versus no sealant was not statistically significant (RR 0.69); subgroup not separately GRADE-rated.
1 finding from 1 review
Optical/esthetic improvement (visual-tactile assessment) · Patients with post-orthodontic white spot lesions (WSL)
Resin infiltration produced significantly greater optical improvement of white spot lesions than untreated (naturally remineralizing) controls (SMD 1.24, 95% CI 0.59 to 1.88; moderate certainty).
4 findings from 1 review
SMD 1.24 [0.59, 1.88]
3 studies · 949 participants
Moderate
SMD 2.34 [1.68, 3.01]
1 study · 66 participants
GRADE not reported
SMD 0.63 [0.26, 1.01]
1 study · 115 participants
GRADE not reported
Show 1 more finding
Initiation of white spot lesions (WSL), visual-tactile assessment · People receiving orthodontic treatment with fixed appliances (upper and/or lower full arch)
Fluoride-releasing coating material did not show a statistically significant reduction in new white spot lesions versus non-fluoride coating (very low certainty).
1 finding from 1 review
Initiation of white spot lesions (WSL), visual-tactile assessment · People receiving orthodontic treatment with fixed appliances (upper and/or lower full arch)
Glass ionomer cement did not show a statistically significant difference in new white spot lesions versus resin adhesive (very low certainty).
1 finding from 1 review
Initiation of white spot lesions (WSL), visual-tactile assessment · Patients of any age (11-40 years) receiving comprehensive/fixed orthodontic treatment with fixed appliances
There is no clear difference in WSL initiation between glass ionomer cement and resin adhesive for bracket bonding (RR 0.72, not significant); certainty of evidence is very low.
1 finding from 1 review
Initiation of white spot lesions (WSL), visual-tactile assessment · People receiving orthodontic treatment with fixed appliances (upper and/or lower full arch)
Sealant use reduced the incidence of new white spot lesions versus no sealant (very low certainty).
1 finding from 1 review
Initiation of white spot lesions (WSL), visual-tactile assessment · Patients of any age (11-40 years) receiving comprehensive/fixed orthodontic treatment with fixed appliances
For compomer-based bonding agents, fluoride release did not significantly change WSL initiation (RR 0.71); subgroup not separately GRADE-rated.
1 finding from 1 review